Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk [PDF]
, 2016 Control of lipid levels is one of the most effective strategies for cardiovascular (CV) event prevention. In fact, many clinical trials have clearly demonstrated that low-density lipoprotein cholesterol (LDL-C) lowering, primarily with statins, reduces ...
AGABITI ROSEI, Enrico, SALVETTI, Massimo
core +1 more source
Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.Background Coronary heart disease (CHD) is a leading cause of cardiovascular mortality worldwide, with its pathogenesis being complex and not yet fully understood. The rapid development of genomics, especially in epigenetic research, has provided essential tools for identifying new pathogenic targets. This study is aimed at systematically exploring the
Junchi Guo +4 more
wiley +1 more source
PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. [PDF]
, 2015 BACKGROUND & AIMS: Hepatitis C virus (HCV) associates with lipoproteins to form "lipoviral particles" (LVPs) that can facilitate viral entry into hepatocytes.
Bassendine, MF +13 more
core +2 more sources
Cleavage of endogenous gamma ENaC and elevated abundance of alpha ENaC are associated with increased Na+ transport in response to apical fluid volume expansion in human H441 airway epithelial cells [PDF]
, 2011 Using human H441 airway epithelial cells cultured at air–liquid interface (ALI), we have uniquely correlated the functional response to apical fluid volume expansion with the abundance and cleavage of endogenous α- and γENaC proteins in the apical ...
Baines, DL, Selvanathar, IA, Tan, CD
core +2 more sources
The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression [PDF]
, 2017 Aims The deacetylase sirtuin 1 (Sirt1) exerts beneficial effects on lipid metabolism, but its roles in plasma LDL-cholesterol regulation and atherosclerosis are controversial.
Arsiwala, Tasneem +17 more
core
A short review of proprotein convertase subtilisin/kexin type 9 inhibitors
Reviews in Cardiovascular Medicine, 2019 Cardiovascular disease is the leading cause of morbidity and mortality globally, as estimated by the World Health Organization, where in 2016, 15.2 million deaths were attributed to ischemic heart disease and stroke. It is therefore essential to try to reduce the incidence of Cardiovascular disease by controlling modifiable risk factors. One such major
openaire +2 more sources
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis [PDF]
, 2020 Robert P. Giugliano +12 more
openalex +1 more source
Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.
Clinical and experimental rheumatology, 2020 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation, and which has been linked to cardiovascular risk. The purpose of the present study was to examine whether PCSK9 serum levels are disrupted in patients with systemic sclerosis (SS ...
Ferraz Amaro, Iván +6 more
openaire +2 more sources
Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum [PDF]
, 2014 Alexander Colbert +5 more
openalex +1 more source
Clinical Case ReportsKey Clinical Message Recent data reveal phenotypic HoFH patients may be responsive to PCSK9 inhibitors, challenging prior assumptions. Genetic testing advancements now more accurately forecast patient responses to these therapies, improving treatment ...
Ryosuke Tani +5 more
doaj +1 more source